ESPR
Esperion Therapeutics, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$3.18
+0.00%Oct 1, 2026, 20:58 UTC
Achieve Life Sciences, Inc. appointed Benjamin Halladay as Chief Financial Officer and principal financial officer, effective October 5, 2026.
Jun 1, 2026, 00:00 UTC
Esperion Therapeutics, Inc. elected J. Martin Carroll and Sheldon L. Koenig as Class I Directors, effective May 28, 2026.